Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature

Table 1 Some blood test of the patient

Time	November 18, 2021	November 26, 2021	December 1, 2021	December 7, 2020
White blood cell	10.3×108/L (3.5-9.5)	10.01×108/L (3.5-9.5)	9.28×108/L (3.5-9.5)	10.76×108/L (3.5-9.5)
Red blood cell	2.68×1012/L (3.8-5.1)	3.01×1012/L (3.8-5.1)	2.86×1012/L (3.8-5.1)	2.63×1012/L (3.8-5.1)
Hemoglobin	78 g/L (115-150)	98 g/L (115-150)	97.9 g/L (115-150)	89.3 g/L (115-150)
Thrombocyte	115×109/L (125-350)	124×109/L (125-350)	135×109/L (125-350)	133×109/L (125-350)
C-reactive protein	22.07 mg/L (0-10)		60.5 mg/L (0-10)
Erythrocyte sedimentation rate			44 mm/h (0-22)	51 mm/h (0-22)
Procalcitonin	0.05 ng/mL (< 0.05)	0.05 ng/mL (< 0.05)	0.09 ng/mL (< 0.05)
D-dimer	0.83 ng/mL (< 0.5 mg/L)		646 ng/mL (< 0.5 mg/L)
Immunoglobulin G (IgG)			22.2 g/L (7.0-12.6)
ANA reaction			Positive
ANA drop degree			0.486
Anti-SSA/Ro antibody			Strongly positive (+++)
Anti-SSB			Positive (++)
Interleukin-6			39.26 pg/mL (0-7)